DUBLIN--(BUSINESS WIRE)--The "Treanda/Bendeka" report has been added to ResearchAndMarkets.com's offering.
Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent. The exact mechanism of action of the drug is still not fully known, but it is a mechlorethamine derivative which has the ability to cause crosslinking between the DNA strands through covalent bond formation. Several pathways have been associated with the cytotoxic activity of Treanda, including the initiation of a p53-dependent stress response and apoptosis due to the induction of significant DNA strand breaks, the inhibition of mitotic checkpoints in the affected cells, and the induction of mitotic catastrophe.
Analyst Outlook
Treanda (bendamustine; Teva/Mundipharma/Eisai) is indicated in the EU for the treatment of newly diagnosed multiple myeloma (NDMM) in combination with prednisone (EMA, 2018; electronic Medicines Compendium, 2018). In the US, the author's MM primary research survey indicates significant off-label use of Treanda and its rapid-infusion formulation, Bendeka.
In Japan, Treanda is also used off-label for the treatment of MM, and The author expects that the potential approval of Bendeka for non-Hodgkin's lymphoma (NHL) in the first half of 2023 will lead to its off-label use for MM. The generic version of bendamustine's powdered formulation is expected to erode sales of Treanda, and to some extent Bendeka, in the US from 2019 onwards.
Key Topics Covered:
OVERVIEW
Drug Overview
Product Profiles
Treanda: Multiple myeloma
Treanda: NHL: Mantle cell lymphoma (MCL)
Treanda/Bendeka: Chronic lymphocytic leukemia (CLL)
Treanda/Bendeka: NHL: Follicular lymphoma (FL)
LIST OF FIGURES
Figure 1: Treanda/Bendeka for multiple myeloma - SWOT analysis
Figure 2: The authors drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 3: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: Treanda for mantle cell lymphoma - SWOT analysis
Figure 5: The authors drug assessment summary of Treanda in mantle cell lymphoma
Figure 6: The authors drug assessment summary of Treanda/Bendeka for CLL
Figure 7: Treanda sales for CLL across the US, Japan, and five major EU markets, by country, 2017-26
Figure 8: Bendeka sales for CLL in the US, 2017-26
Figure 9: Treanda/Bendeka for follicular lymphoma - SWOT analysis
Figure 10: The authors drug assessment summary of Treanda/Bendeka for follicular lymphoma
Figure 11: Treanda/Bendeka sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017-26
LIST OF TABLES
Table 1: Treanda/Bendeka drug profile
Table 2: Treanda early-phase trial data in multiple myeloma
Table 3: Patients receiving Treanda or generic bendamustine in the five major EU markets (%), by country
Table 4: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Patients treated with Treanda/Bendeka across the US, Japan, and five major EU markets, by country, 2017-26
Table 6: Treanda drug profile
Table 7: Treanda pivotal trial data in mantle cell lymphoma
Table 8: Treanda/Bendeka drug profile
Table 9: Approval history of Treanda/Bendeka for CLL in the US, Japan, and five major EU markets
Table 10: Trials of Treanda for CLL
Table 11: Trials of Bendeka for CLL
Table 12: Treanda/Bendeka for CLL - SWOT analysis
Table 13: Uptake of generic bendamustine in the EU, by country
Table 14: Treanda/Bendeka drug profile
Table 15: Treanda/Bendeka pivotal trial data in follicular lymphoma
Table 16: Treanda/Bendeka other clinical trial data in follicular lymphoma
Table 17: Treanda/Bendeka sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
For more information about this report visit https://www.researchandmarkets.com/r/a7pidh
